Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Express Scripts
Julphar
US Army
Chinese Patent Office
Baxter
Argus Health
Harvard Business School
Teva
Deloitte

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,078,925

« Back to Dashboard

Which drugs does patent 9,078,925 protect, and when does it expire?

Patent 9,078,925 protects ABSORICA and is included in one NDA.

This patent has ten patent family members in eight countries.
Summary for Patent: 9,078,925
Title:Pharmaceutical semi-solid composition of isotretinoin
Abstract: The invention relates to an oral pharmaceutical composition of isotretinoin at least two excipients, one of the excipients being a hydrophilic excipient having an HLB value greater than or equal to 10 and the other excipient being an oily vehicle. The oral pharmaceutical composition is substantially devoid of food effect as characterized by a dissolution profile wherein at least 70% of the oral pharmaceutical composition is dissolved after about four hours in a USP2 dissolution apparatus at a paddle speed of 100 rpm, and a dissolution media composed of 900 mL of pH 7.5 buffer containing 0.11% pancreatin, 4.7% cholic acid, 0.14% sodium dihydroxide phosphate and 0.5% sodium hydroxide at 37.degree. C.
Inventor(s): DeBoeck; Arthur M. (Gurabo, PR), Vanderbist; Francis (Brussels, BE), Servais; Cecile (Mehaigne, BE), Baudier; Philippe (Brussels, BE)
Assignee: GALEPHAR PHARMACEUTICAL RESEARCH, INC. (Humacao, PR)
Application Number:14/133,073
Patent Claim Types:
see list of patent claims
Composition; Formulation; Device; Dosage form;

Drugs Protected by US Patent 9,078,925

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sun Pharm Inds Inc ABSORICA isotretinoin CAPSULE;ORAL 021951-001 May 25, 2012 BX RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Sun Pharm Inds Inc ABSORICA isotretinoin CAPSULE;ORAL 021951-002 May 25, 2012 BX RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Sun Pharm Inds Inc ABSORICA isotretinoin CAPSULE;ORAL 021951-005 Aug 15, 2014 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Sun Pharm Inds Inc ABSORICA isotretinoin CAPSULE;ORAL 021951-003 May 25, 2012 BX RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Sun Pharm Inds Inc ABSORICA isotretinoin CAPSULE;ORAL 021951-006 Aug 15, 2014 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Sun Pharm Inds Inc ABSORICA isotretinoin CAPSULE;ORAL 021951-004 May 25, 2012 BX RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,078,925

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,435,427 Pharmaceutical semi-solid composition of isotretinoin ➤ Subscribe
8,367,102 Pharmaceutical semi-solid composition of isotretinoin ➤ Subscribe
9,089,534 Pharmaceutical semi-solid composition of isotretinoin ➤ Subscribe
8,952,064 Pharmaceutical semi-solid composition of isotretinoin ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,078,925

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal 1318791 ➤ Subscribe
Spain 2225600 ➤ Subscribe
European Patent Office 2964195 ➤ Subscribe
European Patent Office 1318791 ➤ Subscribe
Germany 60104206 ➤ Subscribe
Canada 2836228 ➤ Subscribe
Canada 2423170 ➤ Subscribe
Australia 8943801 ➤ Subscribe
Austria 270544 ➤ Subscribe
World Intellectual Property Organization (WIPO) 0224172 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Fish and Richardson
Deloitte
Citi
Medtronic
UBS
Queensland Health
Merck
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot